-
Iran fires back at Trump's threat to declare Hormuz a US territory
-
'Like we were on a trampoline': Indonesia quake kills 20, thousands flee
-
No monkey business: India 'whisperers' guard world championships
-
Australia run riot to crush Japan 56-17 in Townsville
-
Steady India 101-1 at lunch in first Sri Lanka Test
-
Stolen Matisse works tied to infamous art thief in Brazil
-
Faced with historic drought, the Dutch rethink water management
-
Hasan strikes twice for Bangladesh to reduce Australia to 51-2
-
Pallister holds off Ledecky to win Pan Pacs 400m free title
-
Powerful quake off Indonesia kills 20, sparks mass evacuations
-
India's Modi woos youth with free coaching, AI training
-
Mehidy half-century steers Bangladesh to 228-run lead in Australia Test
-
Mehidy half-century steers Bangladesh to big lead in Australia Test
-
Japan defence minister visits war shrine, PM stays away
-
Powerful quake off Indonesia sparks mass evacuations
-
Viennese woman sues city over 'discriminatory' toilet fees
-
Poweful quake off Indonesia sparks mass evacuations
-
Venezuelan amputees adjust to new life after quakes
-
LA Olympics has to allow politicians on the bus, just not behind the wheel - Coe
-
Venezuela frees 131 prisoners amid post-Maduro transition talks
-
No.1 Scheffler fires sizzling 61 to seize PGA St. Jude lead
-
Arteta tells Arsenal fans not to fret over his future
-
Venezuela frees more political prisoners amid post-Maduro talks
-
Mexico's Indigenous chief justice hits back at discrimination
-
Werro upstages Hodgkinson to win thrilling Euro 800m gold
-
Werro wins 800m race for the ages, Warholm and Tamberi hit four
-
Werro upstages Hodgkinson to win Euro 800m gold
-
Jimenez rescues dramatic Wolves draw in Championship opener
-
Hurricane poised to hit Hawaii as El Nino stirs Pacific
-
Taliban govt to mark five years ruling Afghanistan
-
Ex-Cambridge professor at centre of plagiarism scandal found dead
-
Stocks slip in cautious trading after weak US retail sales data
-
Wildfire threatens Canada wine region
-
Gramercy Networks Announces New Global Ultra-Low Latency Financial Network Connecting Major Trading Hubs
-
'Normal guy' turned killer over US insurance industry grievances
-
NFL bans Falcons defender Pearce eight games for domestic violence
-
Norway's hurdles king Warholm wins fourth European title
-
US says 19 million recalled eggs pose deadly risk
-
Liverpool deal with Bezos consortium raises stakes in US battle for Premier League power
-
Former Cincinnati contenders suffer contrasting first-round fates
-
Colombia hopes for miracles as search for quake victims goes on
-
Argentina's Romero confirms Tottenham exit as Atletico move looms
-
Popovici, Quadarella mine more gold at Europeans as Marchand flexes in butterfly
-
Homeless, jobless: Colombia quake survivors 'left with nothing'
-
'I shot Mr Thompson': Stunning confession in US health exec's slaying
-
Cubans find rest on rooftops as blackouts drive them from home
-
San Francisco to host 2028 MLB All-Star Game
-
World champ McIntosh crashes out of Pan Pacs 400m free
-
Trump dismisses concerns over conditions on US aircraft carrier
-
T'Wolves set Garnett celebration for Celtics clash
US greenlights pig kidney transplant trials
Two US biotech companies say the Food and Drug Administration has cleared them to conduct clinical trials of their gene-edited pig kidneys for human transplants.
United Therapeutics along with another company, eGenesis, have been working since 2021 on experiments implanting pig kidneys into humans: initially brain-dead patients and more recently living recipients.
Advocates hope the approach will help address the severe organ shortage. More than 100,000 people in the United States are awaiting transplants, including over 90,000 in need of kidneys.
United Therapeutics's approval, announced Monday, allows the company to advance its technology toward a licensed product if the trial succeeds.
The study authorization was hailed as a "significant step forward in our relentless mission to expand the availability of transplantable organs," by Leigh Peterson, the company's executive vice president.
The trial will initially enroll six patients with end-stage renal disease before expanding to as many as 50, United Therapeutics said in a statement. The first transplant is expected in mid-2025.
Meanwhile, rival eGenesis said it had received FDA approval in December for a separate three-patient kidney study.
"The study will evaluate patients with kidney failure who are listed for a transplant but who face a low probability of receiving a deceased donor offer within a five-year timeframe," the company said.
Xenotransplantation -- transplanting organs from one species to another -- has been a tantalizing yet elusive goal for science.
Early experiments in primates faltered, but advances in gene editing and immune system management have brought the field closer to reality.
Pigs have emerged as ideal donors: they grow quickly, produce large litters, and are already part of the human food supply.
United Therapeutics said trial patients would be monitored for life, assessing survival rates, kidney function, and the risk of zoonotic infections -- diseases that jump from animals to humans.
Currently, there is only one living human recipient of a pig organ: Towana Looney, a 53-year-old from Alabama who received a United Therapeutics kidney on November 25, 2024.
She is also the longest-surviving recipient, having lived with a pig kidney for 71 days as of Tuesday. David Bennett of Maryland received a pig heart in 2022 and survived 60 days.
J.Horn--BTB